Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880248 | 0.85 | AOC3 (0.57) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL5179460 | 0.85 | AOC3 (0.57) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4886677 | 0.85 | AOC3 (0.57) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL15251899 | 0.85 | AOC3 (0.60) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL12947691 | 0.85 | AOC3 (0.60) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL971613 | 0.85 | AOC3 (0.60) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL15251898 | 0.84 | AOC3 (0.58) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL972905 | 0.84 | SMN1; SMN2 (0.66) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL974654 | 0.84 | AOC3 (0.58) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL972138 | 0.84 | AOC3 (0.65) | AOC3SMN1; SMN2KMT2AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2650287-B9 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2650287-B1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2676955-A1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-2650287-A1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2639229-A2 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8507690-B2 | Thiazole derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507690-B2 | Thiazole derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2252604-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-Tech Ueno, Ltd. (JP) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009096609-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, TAS1R1, VAPA | AOC3 438/4885SMN1; SMN2 879/4885KMT2A 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.